Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10207) 10207
Publication (1190) 1190
Newsletter (727) 727
Book Review (112) 112
Magazine Article (58) 58
Book Chapter (40) 40
Newspaper Article (31) 31
Dissertation (21) 21
Trade Publication Article (14) 14
Conference Proceeding (10) 10
Web Resource (9) 9
Paper (8) 8
Government Document (4) 4
Journal / eJournal (3) 3
Data Set (2) 2
Book / eBook (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azithromycin (7752) 7752
humans (5941) 5941
index medicus (3404) 3404
female (3115) 3115
male (3108) 3108
anti-bacterial agents - therapeutic use (2632) 2632
azithromycin - therapeutic use (2397) 2397
infectious diseases (2065) 2065
adult (1995) 1995
microbiology (1853) 1853
pharmacology & pharmacy (1849) 1849
antibiotics (1582) 1582
anti-bacterial agents - pharmacology (1477) 1477
middle aged (1407) 1407
azithromycin - pharmacology (1213) 1213
animals (1151) 1151
azithromycin - administration & dosage (1141) 1141
research (1141) 1141
anti-bacterial agents - administration & dosage (1107) 1107
erythromycin (1078) 1078
treatment outcome (1068) 1068
microbial sensitivity tests (1062) 1062
clarithromycin (1060) 1060
adolescent (1043) 1043
child (974) 974
infections (957) 957
infection (929) 929
immunology (905) 905
aged (896) 896
drug therapy (808) 808
macrolides (788) 788
children (759) 759
health aspects (758) 758
medicine, general & internal (756) 756
care and treatment (726) 726
child, preschool (712) 712
risk factors (658) 658
analysis (642) 642
anti-bacterial agents - adverse effects (596) 596
dosage and administration (581) 581
therapy (577) 577
infant (572) 572
azithromycin - adverse effects (555) 555
pharmacokinetics (551) 551
drug resistance, bacterial (541) 541
respiratory system (529) 529
prevalence (524) 524
pediatrics (504) 504
resistance (500) 500
young adult (487) 487
ciprofloxacin (483) 483
diagnosis (471) 471
drug resistance (471) 471
pneumonia (465) 465
drug therapy, combination (460) 460
prevention (451) 451
research article (449) 449
antimicrobial resistance (439) 439
susceptibility (437) 437
bacteria (430) 430
mice (430) 430
administration, oral (427) 427
efficacy (426) 426
medical research (426) 426
doxycycline (425) 425
macrolide antibiotics (416) 416
inflammation (412) 412
epidemiology (408) 408
chlamydia trachomatis (404) 404
anti-bacterial agents - pharmacokinetics (400) 400
disease (400) 400
antimicrobial agents (393) 393
erythromycin - pharmacology (388) 388
abridged index medicus (384) 384
drug administration schedule (381) 381
chlamydia infections - drug therapy (379) 379
time factors (371) 371
macrolide (369) 369
medicine (363) 363
in-vitro (362) 362
clinical trials (350) 350
azithromycin - pharmacokinetics (349) 349
medicine, experimental (345) 345
retrospective studies (341) 341
double-blind (339) 339
cystic fibrosis (337) 337
trachoma (337) 337
drugs (332) 332
pregnancy (326) 326
prospective studies (325) 325
ophthalmology (323) 323
drug resistance in microorganisms (321) 321
mortality (317) 317
usage (315) 315
ceftriaxone (314) 314
dose-response relationship, drug (309) 309
double-blind method (308) 308
erythromycin - analogs & derivatives (306) 306
follow-up studies (298) 298
aged, 80 and over (297) 297
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10223) 10223
French (194) 194
Spanish (128) 128
German (116) 116
Japanese (104) 104
Russian (74) 74
Chinese (66) 66
Portuguese (37) 37
Italian (30) 30
Croatian (28) 28
Polish (23) 23
Korean (18) 18
Turkish (17) 17
Bulgarian (8) 8
Czech (6) 6
Danish (6) 6
Persian (6) 6
Norwegian (5) 5
Dutch (4) 4
Romanian (4) 4
Hungarian (3) 3
Finnish (2) 2
Hebrew (2) 2
Icelandic (2) 2
Slovak (2) 2
Swedish (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Azithromycin: Mechanisms of action and their relevance for clinical applications
by Parnham, Michael J and Haber, Vesna Erakovic and Giamarellos-Bourboulis, Evangelos J and Perletti, Gianpaolo and Verleden, Geert M and Vos, Robin
Pharmacology and Therapeutics, ISSN 0163-7258, 08/2014, Volume 143, Issue 2, pp. 225 - 245
Azithromycin is a macrolide antibiotic which inhibits bacterial protein synthesis, quorum-sensing and reduces the formation of biofilm. Accumulating... 
Macrolide antibiotic | Mechanisms of action | Pharmacokinetics | Immunomodulation | Azithromycin | Clinical efficacy | LOW-DOSE AZITHROMYCIN | COMMUNITY-ACQUIRED PNEUMONIA | VENTILATOR-ASSOCIATED PNEUMONIA | LONG-TERM AZITHROMYCIN | FACTOR-KAPPA-B | CYSTIC-FIBROSIS BRONCHIECTASIS | OBSTRUCTIVE PULMONARY-DISEASE | BRONCHIOLITIS OBLITERANS SYNDROME | CHRONIC BACTERIAL PROSTATITIS | PHARMACOLOGY & PHARMACY | IMMEDIATE-RELEASE FORMULATIONS | Epithelial Cells - metabolism | Cytokines - metabolism | Bacterial Infections - drug therapy | Humans | Intracellular Signaling Peptides and Proteins - metabolism | Phagocytes - metabolism | Immunomodulation - physiology | Azithromycin - pharmacology | Bacterial Infections - physiopathology | Transcription Factors - metabolism | Azithromycin - pharmacokinetics | Lysosomes - metabolism | Macrolides - pharmacokinetics | Anti-Bacterial Agents - pharmacokinetics | Drug Resistance, Bacterial - physiology | Macrolides - pharmacology | Anti-Bacterial Agents - pharmacology | Phospholipids - metabolism | Drug Resistance, Bacterial - genetics | Respiratory tract diseases | Bacterial infections | Blood lipids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Azithromycin as treatment for Cryptosporidiosis in human immunodeficiency virus disease
by Kadappu, K. K and Nagaraja, M. V and Rao, P. V and Shastry, B. A
Azithromycin as treatment for Cryptosporidiosis in human immunodeficiency virus disease, 12/2002
Background: Cryptosporidiosis caused by the protozoa Cryptosporidium, is the common cause of diarrhoea in Acquired Immune Deficiency Syndrome (AIDS). Aim: To... 
Cryptosporidiosis, Azithromycin, AIDS
Journal
Details down arrow
3. Study - Comparison of oral azithromycin pulse with daily doxycycline in the treatment of acne vulgaris
by Singhi, M. K and Ghiya, B. C and Dhabhai, R. K
Study - Comparison of oral azithromycin pulse with daily doxycycline in the treatment of acne vulgaris, 12/2003
Introduction: Oral azithromycin has been advocated by some in the treatment of acne. However, its efficacy has not been established. Material and Methods: This... 
Azithromycin, Acne vulgaris, Doxycycline
Journal
Details down arrow
4. Clinical observation of azithromycin combined vaginal antibacterial gel on female genital tract mycoplasma infection
by Miao, H and Liu, F-Z and Qi, Z-H
Xiandai Yaowu Yu Linchuang / Drugs & Clinic, ISSN 1674-5515, 05/2013, Volume 28, Issue 3, pp. 361 - 363
Objective To observe the effect of azithromycin combined with vaginal antibacterial gel in the treatment of female genital tract mycoplasma infection in... 
Azithromycin
Journal Article
Details down arrow
5. Full Text A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation
by Vos, R and Vanaudenaerde, B.M and Verleden, S.E and De Vleeschauwer, S.I and Willems-Widyastuti, A and Van Raemdonck, D.E and Schoonis, A and Nawrot, T.S and Dupont, L.J and Verleden, G.M
European Respiratory Journal, ISSN 0903-1936, 01/2011, Volume 37, Issue 1, pp. 164 - 172
Azithromycin reduces airway inflammation and improves forced expiratory volume in 1 s (FEV1) in chronic rejection or bronchiolitis obliterans syndrome (BOS)... 
Lung allograft rejection | Bronchiolitis obliterans syndrome | Obliterative bronchiolitis | Azithromycin | Lung transplantation | lung allograft rejection | SURVIVAL | BRONCHIOLITIS-OBLITERANS-SYNDROME | bronchiolitis obliterans syndrome | LONG-TERM AZITHROMYCIN | RECIPIENTS | HEART | THERAPY | RESPIRATORY SYSTEM | MAINTENANCE AZITHROMYCIN | IMMUNOSUPPRESSION | lung transplantation | obliterative bronchiolitis | Double-Blind Method | Graft Rejection - prevention & control | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Inflammation | Transplantation, Homologous | Bronchiolitis Obliterans - prevention & control | Forced Expiratory Volume | Disease-Free Survival | Azithromycin - therapeutic use | Placebos | Adult | Female | Lung Transplantation - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis: The BAT Randomized Controlled Trial
by Altenburg, Josje and de Graaff, Casper S and Stienstra, Ymkje and Sloos, Jacobus H and van Haren, Eric H. J and Koppers, Ralph J. H and van der Werf, Tjip S and Boersma, Wim G
JAMA, ISSN 0098-7484, 03/2013, Volume 309, Issue 12, pp. 1251 - 1259
IMPORTANCE Macrolide antibiotics have been shown beneficial in cystic fibrosis (CF) and diffuse panbronchiolitis, and earlier findings also suggest a benefit... 
LOW-DOSE AZITHROMYCIN | MEDICINE, GENERAL & INTERNAL | ANTIBIOTICS | LONG-TERM AZITHROMYCIN | PSEUDOMONAS-AERUGINOSA | DOUBLE-BLIND | STAPHYLOCOCCUS-AUREUS | MACROLIDE RESISTANCE | CORTICOSTEROIDS | HEALTH-STATUS | CHILDREN | Sputum - microbiology | Double-Blind Method | Bacterial Infections - etiology | Humans | Middle Aged | Respiratory Tract Infections - prevention & control | Drug Resistance, Bacterial | Male | Inflammation | Lung - physiopathology | Biomarkers - blood | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Bacterial Infections - prevention & control | Bronchiectasis - complications | Azithromycin - therapeutic use | Quality of Life | Adult | Female | Respiratory Tract Infections - etiology | Aged | Anti-Bacterial Agents - adverse effects | Respiratory Function Tests | Clinical trials | Cystic fibrosis | Antibiotics | Medical treatment | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
by Wong, Conroy, Dr and Jayaram, Lata, FRACP and Karalus, Noel, FRACP and Eaton, Tam, FRACP and Tong, Cecilia, RN and Hockey, Hans, MSc and Milne, David, FRANZCR and Fergusson, Wendy, BHSc and Tuffery, Christine, BN and Sexton, Paul, FRACP and Storey, Louanne, BSc and Ashton, Toni, Prof
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9842, pp. 660 - 667
Summary Background Azithromycin is a macrolide antibiotic with anti-inflammatory and immunomodulatory properties. We tested the hypothesis that azithromycin... 
Internal Medicine | LONG-TERM | MEDICINE, GENERAL & INTERNAL | THERAPY | PSEUDOMONAS-AERUGINOSA | PARAMETERS | MACROLIDES | CHILDREN | Double-Blind Method | Drug Administration Schedule | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Treatment Outcome | Secondary Prevention | Azithromycin - administration & dosage | Cystic Fibrosis - complications | Vital Capacity - drug effects | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Azithromycin - therapeutic use | Bronchiectasis - prevention & control | Quality of Life | Adult | Female | Aged | Anti-Bacterial Agents - adverse effects | Anti-Bacterial Agents - administration & dosage | Bronchiectasis - physiopathology | Bronchiectasis - etiology | Prevention | Usage | Bronchiectasis | Research | Azithromycin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The Story of Azithromycin
by Banić Tomišić, Z
Kemija u Industriji, ISSN 0022-9830, 12/2011, Volume 60, Issue 12, pp. 603 - 617
The invention of azithromycin (1, Figure 1), the active pharmaceutical ingredient of the antibiotic Sumamed (Croatian brand name by PLIVA; Zithromax by Pfizer... 
Azithromycin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects
by Zheng, Songmao and Matzneller, Peter and Zeitlinger, Markus and Schmidt, Stephan
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 11/2014, Volume 58, Issue 11, pp. 6675 - 6684
Recent clinical trials indicate that the use of azithromycin is associated with the emergence of macrolide resistance. The objective of our study was to... 
LUNG-TISSUE | IN-VITRO | STREPTOCOCCUS-PNEUMONIAE | LONG-TERM AZITHROMYCIN | PHAGOCYTIC-CELLS | DOUBLE-BLIND | MACROLIDE AZITHROMYCIN | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | ACCUMULATION | ORAL AZITHROMYCIN | Anti-Bacterial Agents - blood | Azithromycin - blood | Humans | Drug Resistance, Bacterial | Half-Life | Male | Respiratory Tract Infections - drug therapy | Healthy Volunteers | Microbial Sensitivity Tests | Respiratory Tract Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Azithromycin - pharmacokinetics | Azithromycin - therapeutic use | Anti-Bacterial Agents - pharmacokinetics | Adult | Pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Current views on chronic rejection after lung transplantation
by Verleden, Geert M and Vos, Robin and Vanaudenaerde, Bart and Dupont, Lieven and Yserbyt, Jonas and Van Raemdonck, Dirk and Verleden, Stijn
Transplant International, ISSN 0934-0874, 10/2015, Volume 28, Issue 10, pp. 1131 - 1139
Summary Chronic lung allograft dysfunction (CLAD) was recently introduced as an overarching term mainly to classify patients with chronic rejection after lung... 
azithromycin‐responsive allograft dysfunction | chronic lung allograft dysfunction | lung transplantation | bronchiolitis obliterans syndrome | chronic rejection | restrictive allograft syndrome | azithromycin-responsive allograft dysfunction | Postoperative Complications - etiology | Bronchiolitis Obliterans - etiology | Gastroesophageal Reflux - physiopathology | Graft Rejection - physiopathology | Humans | Neutrophils - drug effects | Gastroesophageal Reflux - etiology | Bronchiolitis Obliterans - surgery | Graft Rejection - diagnosis | Allografts - immunology | Disease Progression | Azithromycin - pharmacology | Forced Expiratory Volume | Fundoplication | Gastroesophageal Reflux - surgery | Bronchiolitis Obliterans - physiopathology | Lung Transplantation | Phenotype | Azithromycin - therapeutic use | Graft Rejection - classification | Graft Rejection - immunology | Chronic Disease | SURVIVAL | SURGERY | BRONCHIOLITIS-OBLITERANS-SYNDROME | AZITHROMYCIN THERAPY | SYNDROME BOS | AIRWAY NEUTROPHILIA | TRANSPLANTATION | HEART-LUNG | GASTROESOPHAGEAL-REFLUX DISEASE | DYSFUNCTION | DIAGNOSTIC-CRITERIA | Transplantation of organs, tissues, etc | Respiratory tract diseases | Transplants & implants | Respiratory diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Photocatalytic degradation of azithromycin using GO@Fe.sub.3O.sub.4/ ZnO/ SnO.sub.2 nanocomposites
by Sayadi, Mohammad Hossein and Sobhani, Sara and Shekari, Hossein
Journal of Cleaner Production, ISSN 0959-6526, 09/2019, Volume 232, p. 127
Sewage output contains a wide range of organic materials, such as pharmaceutical compounds. These compounds have harmful effects on the environment, such as... 
Pollution | Analysis | Azithromycin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation
by Corris, Paul A and Ryan, Victoria A and Small, Therese and Lordan, James and Fisher, Andrew J and Meachery, Gerard and Johnson, Gail and Ward, Chris
Thorax, ISSN 0040-6376, 05/2015, Volume 70, Issue 5, pp. 442 - 450
Background We conducted a placebo-controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Methods We... 
NEUTROPHILIA | RESPIRATORY SYSTEM | LONG-TERM AZITHROMYCIN | MAINTENANCE AZITHROMYCIN | ASTHMA | RISK | RECIPIENTS | CHRONIC REJECTION | BRONCHOALVEOLAR LAVAGE | Double-Blind Method | Bronchiolitis Obliterans - etiology | Humans | Middle Aged | Male | Treatment Outcome | Lung Transplantation - adverse effects | Syndrome | Bronchiolitis Obliterans - diagnosis | Forced Expiratory Volume | Anti-Bacterial Agents - therapeutic use | Azithromycin - therapeutic use | Adult | Female | Bronchiolitis Obliterans - drug therapy | Clinical trials | Usage | Care and treatment | Dosage and administration | Azithromycin | Bronchiolitis | Studies | Clinical medicine | Transplants & implants | Drug dosages | Mortality | Neutrophils | 1506 | Lung Transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text A new strategy for taste masking of azithromycin antibiotic: Development, characterization, and evaluation of azithromycin titanium nanohybrid for masking of bitter taste using physisorption and panel testing studies
by Amin, Fazli and Khan, Shahzeb and Shah, Syed Muhammad Hassan and Rahim, Haroon and Hussain, Zahid and Sohail, Muhammad and Ullah, Riaz and Alsaid, Mansour S and Shahat, Abdelaaty A
Drug Design, Development and Therapy, ISSN 1177-8881, 2018, Volume 12, pp. 3855 - 3866
Background: The obnoxious bitter taste of orally taken antibiotics is one of the biggest problems in the treatment of children. The pediatric population cannot... 
Azithromycin–TiO2 nanohybrid | AZN | Azithromycin | TNPs | Dissolution | Physisorption | Titanium dioxide nanoparticles | CHEMISTRY, MEDICINAL | STABILITY | titanium dioxide nanoparticles | dissolution | NANOCRYSTALS | azithromycin | physisorption | FORMULATION | ADSORPTION | SOLUBILITY | NANOPARTICLES | IN-VITRO | azithromycin-TiOnanohybrid | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | OPTIMIZATION | FABRICATION | Azithromycin - chemistry | Titanium - pharmacology | Nanoparticles - chemistry | Humans | Molecular Conformation | Titanium - chemistry | Healthy Volunteers | Azithromycin - pharmacology | Particle Size | Taste - drug effects | Adsorption | Anti-Bacterial Agents - chemistry | Surface Properties | Anti-Bacterial Agents - pharmacology | Titanium | Health aspects | Titanium dioxide | Analysis | Fourier transforms | Adsorbates | X-ray diffraction | Dosage | Powder | Adsorbents | Nanoparticles | Aqueous solutions | Masking | Children | Psychological stress | Scanning electron microscopy | Stability | X ray powder diffraction | Bitter taste | Accelerated tests | Environmental factors | Liquid chromatography | High-performance liquid chromatography | Pharynx | Dispersion | Studies | Organic chemistry | Palatability | Antibiotics | Taste | Drying | Pediatrics | Particle size | Efficiency | Drug dosages | Pharmacy | Potassium | Pharmaceuticals | Titanium dioxide nanoparticles (TNP) | Physiosorption | Azithromycin (AZ) | Azithromycin- TiO2 Nanohybrid (AZN)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Azithromycin and the Risk of Cardiovascular Death
by Ray, Wayne A and Murray, Katherine T and Hall, Kathi and Arbogast, Patrick G and Stein, C. Michael
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 20, pp. 1881 - 1890
In a large cohort study, patients who took azithromycin had significantly increased risks of cardiovascular death and death from any cause during a 5-day... 
MEDICINE, GENERAL & INTERNAL | TORSADES-DE-POINTES | QT-INTERVAL PROLONGATION | EVENT REPORTING SYSTEM | DRUGS | MACROLIDE | SUDDEN CARDIAC DEATH | PHARMACOEPIDEMIOLOGY | ORAL ERYTHROMYCIN | ADJUSTMENT | PROPENSITY SCORES | Arrhythmias, Cardiac - chemically induced | United States | Humans | Middle Aged | Male | Risk | Death, Sudden, Cardiac - etiology | Incidence | Anti-Bacterial Agents - therapeutic use | Azithromycin - adverse effects | Azithromycin - therapeutic use | Cardiovascular Diseases - mortality | Adult | Female | Anti-Bacterial Agents - adverse effects | Cardiovascular Diseases - chemically induced | Retrospective Studies | Medicaid | Cohort Studies | Dose-response relationship (Biochemistry) | Causes of | Complications and side effects | Cardiovascular diseases | Azithromycin | Levofloxacin | Hospitals | Antibiotics | Amoxicillin | Macrolide antibiotics | Death | Ciprofloxacin | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights